Aug 28, 2022 / 05:00PM GMT
Timothy Power - Bristol-Myers Squibb Company - VP & Head of IR
This is Tim Power from Bristol-Myers Squibb. You're very welcome to our presentation at ESC 2022. As you know, we had some very important data presented this morning for our milvexian secondary stroke study, and we're looking forward to discussing that with you today.
I'm joined for today's presentation by 2 speakers, Samit Hirawat, our Chief Medical Officer and Head of Global Drug Development; and Chris Boerner, our Chief Commercialization Officer.
Moving to Slide 2, I'll refer you to our forward-looking statements. And with that, I'll hand it over to Samit to start the presentation on Slide 3.
Samit Hirawat - Bristol-Myers Squibb Company - Executive VP & Chief Medical Officer of Global Drug Development
Thank you, Tim. It's great to be here with you during ESC to discuss the important Phase II SSP data that were presented earlier today for milvexian.
Let's turn to Slide 4. We are very excited about the profile of milvexian, which we believe has the potential to
Bristol-Myers Squibb Co Investor Event Transcript
Jan 22, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers